Sign inJoin waitlistJoin the waitlist

MM

Megan Mantica

Program Director, Karp Neuro-Oncology Fellowship, UPMC · UPMC Medical Education

Credentials: · · · ·

History

Karp Neuro-Oncology, UPMC Fellowship · UPMC Medical Education
Present
UPMC Medical Education
Present

University of Pittsburgh
2016–2017
University of Pittsburgh
2014–2016
University of Pittsburgh
2013–2014
State University of New York Upstate Medical University
2009–2013

Research

Retrospective study of nivolumab for patients with recurrent high grade gliomas
Journal of Neuro-Oncology · 2018 · First of 4 authors · Corresponding · 26 citations
Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme
Journal of Neuro-Oncology · 2023 · First of 6 authors · Corresponding · 13 citations
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
The Oncologist · 2025 · 11 citations

Jan Drappatz
13 papers
Kalil Abdullah
7 papers
Pascal Zinn
7 papers
FL
Frank Lieberman
3 papers
Zachary Gersey
3 papers · 3 as a resident
Aatur Singhi
2 papers
Dan Zandberg
2 papers
Diwakar Davar
2 papers
Ian Pollack
2 papers
JL
Jason Luke
2 papers
Jeremy Rich
2 papers
JR
John Rhee
2 papers

Clinical trials

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations
Principal investigator · Not yet recruiting · Phase 1
Megan Mantica
2026–2035
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2027
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027